Global Health Limited reported strong financial results for Q3 FY26. Consolidated Total Income increased by 19% year-over-year to INR 11,428 million. EBITDA ex Noida rose by 11% to INR 2,814 million, with a margin of 25.4%. Medanta Noida continues to gain momentum and is now fully operational. The hospital achieved increased revenue from mature and developing hospitals and international patients.
Q3 FY26 Financial Highlights
Global Health Limited announced its consolidated financial results for the quarter ending December 31, 2025, showcasing significant growth in key areas:
- Consolidated Total Income: INR 11,428 million, a 19% increase year-over-year.
- EBITDA (ex-Noida): INR 2,814 million, up by 11% year-over-year, with margins of 25.4%.
- EBITDA (Including Noida): INR 2,494 million, down by 1.7% year-over-year, with margins at 21.8%.
- Profit After Tax (PAT): INR 950 million.
Operational Performance
Key operational metrics also showed positive trends:
- Medanta Noida: Commenced operations in September 2025, generating revenue of INR 343 million.
- Bed Additions: 144 new beds added, including 42 at Patna and 102 at Noida.
- Volume Growth: Robust, with In-patient count up by 14.3% and Out-patient count up by 19.5%.
- ALOS: Improved to 3.02 days, a 6.6% year-over-year improvement.
- Occupancy: Approximately 59% on increased bed capacity.
- ARPOB: INR 67,361, up by 9.9%, driven by ALOS improvement and case mix changes.
Segment Performance
Different hospital segments contributed to the overall growth:
- Matured Hospitals: Revenue of INR 7,020 million, up by 9.4%. EBITDA of INR 1,675 million, up by 6.7%.
- Developing Hospitals (ex Noida): Revenue of INR 3,651 million, up 21.5%. EBITDA of INR 1,156 million, up 13.3%.
- International Patients: Revenue of INR 703 million, up by 29.9%.
- OPD Pharmacy: Revenue of INR 465 million, up by 30.3%.
9M FY26 Performance
The performance for the nine months ending December 31, 2025 was also strong:
- Total Income: INR 33,131 million, up by 17.6% year-over-year.
- EBITDA (ex Noida): INR 8,201 million, up by 15.7%, with margins of 25.0%.
- EBITDA (Including Noida): INR 7,654 million, up by 8.0%, with margins of 23.1%.
- Profit After Tax: INR 4,124 million, up by 8.5%.
Comments from Leadership
Mr. Pankaj Sahni, Group CEO and Director, stated that Medanta delivered a strong performance, supported by increased patient volumes, improved realizations, and steady execution. He noted that Medanta Noida completed its first full quarter of operations, with increased infrastructure and doctor onboarding.
Source: BSE
